Coal tar in dermatology

Reference

• Boffetta P., Jourenkova N., Gustavsson P. Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control 1997; 8: 444–72
   PubMed Web of Science ®Google Scholar
• Donato F., Monarca S., Marchionna G., Rossi A., Cicioni C., Chiesa R., et al. Mortality from cancer and chronic respiratory diseases among workers who manufacture carbon electrodes. Occup Environ Med 2000; 57: 484–7
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer. Coal‐tars and derived product. Polynuclear aromatic compounds, part 4: Bitumens, coal‐tars and derived products, shale‐oils and soots. IARC Monogr Eval Carcinog Risk Chem Hum, 35: 83–159
   PubMedGoogle Scholar
• Partanen T., Boffetta P. Cancer risk in asphalt workers and roofers: Review and meta‐analysis of epidemiologic studies. Am J Ind Med 1994; 26: 721–40
   PubMed Web of Science ®Google Scholar
• Tsai P. J., Shieh H. Y., Lee W. J., Lai S. O. Health‐risk assessment for workers exposed to polycyclic aromatic hydrocarbons (PAHs) in a carbon black manufacturing industry. Sci Total Environ 2001; 278((1–3): )137–50
   PubMedGoogle Scholar
• Stern R. S., Zierler S., Parrish J. A. Skin carcinoma in patients with psoriasis treated with topical tar and artificial ultraviolet radiation. Lancet 1980; i: 732–5
   Google Scholar
• Moy L. S., Chalet M., Lowe N. J. Scrotal squamous cell carcinoma in a psoriatic patient treated with coal tar. J Am Acad Dermatol 1986; 14: 518–19
   PubMed Web of Science ®Google Scholar
• McGarry G. W., Robertson J. R. Scrotal carcinoma following prolonged use of crude coal tar ointment. Br J Urol 1989; 63: 211
   PubMedGoogle Scholar
• Hannuksela‐Svahn A., Pukkala E., Laara E., Poikolainen K., Karvonen J. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000; 114: 587–90
   PubMed Web of Science ®Google Scholar
• Jones S. K., Mackie R. M., Hole D. J., Gillis C. R. Further evidence of the safety of tar in the management of psoriasis. Br J Dermatol 1985; 113: 97–101
   PubMed Web of Science ®Google Scholar
• Larko O., Swanbeck G. Is UVB treatment of psoriasis safe? A study of extensively UVB‐treated psoriasis patients compared with a matched control group. Acta Derm Venereol 1982; 62: 507–12
   PubMedGoogle Scholar
• Maughan W. Z., Muller S. A., Perry H. O., Pittelkow M. R., O'Brien P. C. Incidence of skin cancers in patients with atopic dermatitis treated with coal tar. A 25‐year follow‐up study. J Am Acad Dermatol 1980; 3: 612–15
   PubMed Web of Science ®Google Scholar
• Pittelkow M. R., Perry H. O., Muller S. A., Maughan W. Z., O'Brien P. C. Skin cancer in patients with psoriasis treated with coal tar. A 25‐year follow‐up study. Arch Dermatol 1981; 117: 465–8
   PubMed Web of Science ®Google Scholar
• Diezel W., Gruner S., Anhalt G. J. ATPase positive epidermal Langerhans cells: Inhibition of ATPase by ammonium bituminosulfonate (Ichthyol) and pix lithanthracis. Hautarzt 1992; 43: 22–4
   PubMedGoogle Scholar
• Dodd W. A. TARS. Their role in the treatment of psoriasis. Dermatol Clin 1993; 11: 131–5
   PubMedGoogle Scholar
• Lavker R. M., Grove G. L., Kligman A. M. The atrophogenic effect of crude coal tar on human epidermis. Br J Dermatol 1981; 105: 77–82
   PubMed Web of Science ®Google Scholar
• Bladon P. T., Taylor M., Wood E. J., Cunliffe W. J. Effect of crude coal tar in the mouse‐tail model of psoriasis. Arch Dermatol Res 1985; 277: 121–5
   PubMed Web of Science ®Google Scholar
• Arnold W. P. Tar. Clin Dermatol 1997; 15: 739–44
   PubMed Web of Science ®Google Scholar
• Thami G. P., Sarkar R. Coal tar: Past, present and future. Clin Exp Dermatol 2002; 27: 99–103
   PubMed Web of Science ®Google Scholar
• Roelofzen J. H. J., Khawar A. J. M., Aben K. K. H., Kiemeney L. A. L. M., van Houtum J. L. M., van der Valk P. G. M. Treatment policy of psoriasis and eczema by Dutch and Flemish dermatologists. Neth J Derm Ven 2005; 15: 231–4
   Google Scholar
• Williams R. E., Tillman D. M., White S. I., Barnett E. L., Mackie R. M. Re‐examining crude coal tar treatment for psoriasis. Br J Dermatol 1992; 126: 608–10
   PubMed Web of Science ®Google Scholar
• Young E. The external treatment of psoriasis. A controlled investigation of the effects of coal tar. Br J Dermatol 1970; 82: 510–15
   PubMed Web of Science ®Google Scholar
• Veronikis I. E., Malabanan A. O., Holick M. F. Comparison of calcipotriene (Dovonex) with a coal tar emulsion (Exorex) in treating psoriasis in adults: A pilot study. Arch Dermatol 1999; 135: 474–5
   PubMedGoogle Scholar
• Pinheiro N. Comparative effects of calcipotriol ointment (50 micrograms/g) and 5% coal tar/2% allantoin/0.5% hydrocortisone cream in treating plaque psoriasis. Br J Clin Pract 1997; 51: 16–19
   PubMedGoogle Scholar
• Tham S. N., Lun K. C., Cheong W. K. A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. Br J Dermatol 1994; 131: 673–7
   PubMed Web of Science ®Google Scholar
• Kang S., Lucky A. W., Pariser D., Lawrence I., Hanifin J. M. Long‐term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44((1 suppl))S58–S64
   Web of Science ®Google Scholar
• Reitamo S., Wollenberg A., Schopf E., Perrot J. L., Marks R., Ruzicka T., et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000; 136: 999–1006
   PubMed Web of Science ®Google Scholar
• Van de Kerkhof P. C. Teer in de dermatologie. Neth J Derm Ven 1989; 133: 2067–70
   Google Scholar
• Arnold W. P. Koolteer in de dermatologie. Ook na het jaar 2000?. Ned T Derm Ven 1997; 7: 191–5
   Google Scholar
• Cusano F., Capozzi M., Errico G. Allergic contact dermatitis from coal tar. Contact Dermatitis 1992; 27: 51–2
   PubMedGoogle Scholar
• Goncalo S., Sousa I., Moreno A. Contact dermatitis to coal tar. Contact Dermatitis 1984; 10: 57–8
   PubMedGoogle Scholar
• Riboldi A., Pigatto P. D., Innocenti M. O., Giacchetti A., Morelli M. Contact dermatitis to coal tar in psoriasis. Contact Dermatitis 1986; 14: 187–8
   PubMedGoogle Scholar
• Roesyanto I. D., van den Akker T. W., van Joost T. W. Wood tars allergy, cross‐sensitization and coal tar. Contact Dermatitis 1990; 22: 95–8
   PubMedGoogle Scholar
• Bickers D. R. The carcinogenicity and mutagenicity of therapeutic coal tar: A perspective. J Invest Dermatol 1981; 77: 173–4
   PubMed Web of Science ®Google Scholar
• Dipple A. Formation, metabolism, and mechanism of action of polycyclic aromatic hydrocarbons. Cancer Res 1983; 43: S2422–5
   PubMed Web of Science ®Google Scholar
• Hemminki K. DNA adducts, mutations and cancer. Carcinogenesis 1993; 14: 2007–12
   PubMed Web of Science ®Google Scholar
• Pion I. A., Koenig K. L., Lim H. W. Is dermatologic usage of coal tar carcinogenic? A review of the literature. Dermatol Surg 1995; 21: 227–31
   PubMed Web of Science ®Google Scholar
• Alderson M. R., Clarke J. A. Cancer incidence in patients with psoriasis. Br J Cancer 1983; 47: 857–9
   PubMed Web of Science ®Google Scholar
• Bhate S. M., Sharpe G. R., Marks J. M., Shuster S., Ross W. M. Prevalence of skin and other cancers in patients with psoriasis. Clin Exp Dermatol 1993; 18: 401–4
   PubMed Web of Science ®Google Scholar
• Boffetta P., Gridley G., Lindelof B. Cancer risk in a population‐based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001; 117: 1531–7
   PubMed Web of Science ®Google Scholar
• Frentz G., Olsen J. H. Malignant tumours and psoriasis: A follow‐up study. Br J Dermatol 1999; 140: 237–42
   PubMed Web of Science ®Google Scholar
• Lindelof B., Eklund G., Liden S., Stern R. S. The prevalence of malignant tumors in patients with psoriasis. J Am Acad Dermatol 1990; 22((6 Pt 1))1056–60
   PubMedGoogle Scholar
• Margolis D., Bilker W., Hennessy S., Vittorio C., Santanna J., Strom B. L. The risk of malignancy associated with psoriasis. Arch Dermatol 2001; 137: 778–83
   PubMed Web of Science ®Google Scholar
• Olesen A. B., Engholm G., Storm H. H., Thestrup‐Pedersen K. The risk of cancer among patients previously hospitalized for atopic dermatitis. J Invest Dermatol 2005; 125: 445–9
   PubMedGoogle Scholar
• Olsen J. H., Moller H., Frentz G. Malignant tumors in patients with psoriasis. J Am Acad Dermatol 1992; 27((5 Pt 1))716–22
   PubMed Web of Science ®Google Scholar
• Wang H., Diepgen T. L. Is atopy a protective or a risk factor for cancer? A review of epidemiological studies. Allergy 2005; 60: 1098–111
   PubMed Web of Science ®Google Scholar
• Clonfero E., Zordan M., Cottica D., Venier P., Pozzoli L., Cardin E. L., et al. Mutagenic activity and polycyclic aromatic hydrocarbon levels in urine of humans exposed to therapeutical coal tar. Carcinogenesis 1986; 7: 819–23
   PubMed Web of Science ®Google Scholar
• Clonfero E., Zordan M., Venier P., Paleologo M., Levis A. G., Cottica D., et al. Biological monitoring of human exposure to coal tar. Urinary excretion of total polycyclic aromatic hydrocarbons, 1‐hydroxypyrene and mutagens in psoriatic patients. Int Arch Occup Environ Health 1989; 61: 363–8
   PubMed Web of Science ®Google Scholar
• Godschalk R. W., Ostertag J. U., Moonen E. J., Neumann H. A., Kleinjans J. C., van Schooten F. J. Aromatic DNA adducts in human white blood cells and skin after dermal application of coal tar. Cancer Epidemiol Biomarkers Prev 1998; 7: 767–73
   PubMed Web of Science ®Google Scholar
• Ingelman‐Sundberg M. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res 2001; 482((1–2))11–19
   PubMedGoogle Scholar
• Miller M. C III., Mohrenweiser H. W., Bell D. A. Genetic variability in susceptibility and response to toxicants. Toxicol Lett 2001; 120((1–3))269–80
   PubMedGoogle Scholar